Table 3.

Model Parameters

	Class 1		Class 2
Class Proportions	0.635		0.365
Utility Parameters	Parameter	T-Ratio	Parameter	T-Ratio
(Reference category: Oral – Low frequency 2–3 times/weekly)
Oral – High Frequency (Daily)	1.149	2.36	0.130	0.73
Intravenous – Low Frequency (Fortnightly/Monthly)	0.473	1.04	−0.401	−2.75
Intravenous – High Frequency (2–3 times/weekly)	−0.235	−0.88	−0.907	−4.99
Subcutaneous – Low Frequency (Fortnightly/Monthly)	0.622	1.57	−0.166	−1.11
Subcutaneous – High Frequency (2–3 times/weekly)	−0.439	−1.38	−0.572	−3.84
(Reference category: Free £0)
Out-of-pocket cost – £400/800	−0.028	−0.11	−0.263	−2.12
Out-of-pocket cost – £1200	−0.327	−1.03	−0.402	−2.8
Out-of-pocket cost – £1600	−0.279	−0.79	−0.612	−4.22
(Reference category: 1 year)
Average survival – 3 years	6.101	5.93	0.672	3.89
Average survival – 5 years	9.610	8.29	1.578	9.73
Average survival – 7 years	11.843	9.11	2.194	13.35
Average survival – 9 years	14.034	9.74	2.619	14.51
(Reference category: Long remission period)
Short remission period	−1.986	−7.72	−0.598	−6.72
(Reference category: Low to medium risk of mild-to-moderate side effects)
No mild-to-moderate side effects	0.418	1.12	0.414	2.69
High risk of mild-to-moderate side effects	−0.724	−4.01	−0.181	−1.81
(Reference category: Low risk of severe side effects)
No severe side effects	0.555	1.84	0.545	4.23
High risk of severe side effects	−0.438	−1.82	−0.155	−1.61
Neither treatment (constant)	−4.939	−4.04	−0.267	−1.21
Class membership – Class 1 (Reference category: Class 2)
Constant	0.699	3.46
Living alone	−0.874	−2.59
Diagnosed recently	0.386	1.68
Experienced severe side effects	−0.479	−1.97
419 participants, Number of choice observations: 4190. Log likelihood −1951.59